SynCore BiotechnologyLtd Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Muh-Hwan Su
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.9yrs |
| CEO ownership | n/a |
| Management average tenure | 9.8yrs |
| Board average tenure | 10.5yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -NT$38m |
| Sep 30 2023 | n/a | n/a | -NT$162m |
| Jun 30 2023 | n/a | n/a | -NT$163m |
| Mar 31 2023 | n/a | n/a | -NT$170m |
| Dec 31 2022 | n/a | n/a | -NT$189m |
| Sep 30 2022 | n/a | n/a | -NT$187m |
| Jun 30 2022 | n/a | n/a | -NT$375m |
| Mar 31 2022 | n/a | n/a | -NT$429m |
| Dec 31 2021 | n/a | n/a | -NT$459m |
| Sep 30 2021 | n/a | n/a | -NT$481m |
| Jun 30 2021 | n/a | n/a | -NT$364m |
| Mar 31 2021 | n/a | n/a | -NT$386m |
| Dec 31 2020 | n/a | n/a | -NT$399m |
| Sep 30 2020 | n/a | n/a | -NT$409m |
| Jun 30 2020 | n/a | n/a | -NT$417m |
| Mar 31 2020 | n/a | n/a | -NT$430m |
| Dec 31 2019 | NT$4m | NT$3m | -NT$409m |
| Sep 30 2019 | n/a | n/a | -NT$389m |
| Jun 30 2019 | n/a | n/a | -NT$359m |
| Mar 31 2019 | n/a | n/a | -NT$306m |
| Dec 31 2018 | NT$4m | NT$3m | -NT$294m |
| Sep 30 2018 | n/a | n/a | -NT$270m |
| Jun 30 2018 | n/a | n/a | -NT$253m |
| Mar 31 2018 | n/a | n/a | -NT$247m |
| Dec 31 2017 | NT$3m | NT$2m | -NT$258m |
Compensation vs Market: Insufficient data to establish whether Muh-Hwan's total compensation is reasonable compared to companies of similar size in the TW market.
Compensation vs Earnings: Muh-Hwan's compensation has been consistent with company performance over the past year.
CEO
Muh-Hwan Su
10.9yrs
Tenure
NT$3,854,000
Compensation
Dr. Muh Hwan Su, Ph D, has been President of Syncore Biotechnology Co., Ltd. since June 03, 2013 and served as its Director since Jun 09, 2008 until April 24, 2018.Dr. Su serves as General Manager of SynC...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman of the Board | 15.9yrs | NT$1.05m | no data | |
| President & GM | 10.9yrs | NT$3.85m | no data | |
| VP & Head of Drug Development Department | 8.6yrs | NT$1.49m | no data | |
| Head of Financial & General Affairs Department and Accounting Manager | 10.9yrs | no data | no data | |
| Head of Quality Assurance Department | 7.8yrs | no data | no data |
9.8yrs
Average Tenure
Experienced Management: 4192's management team is seasoned and experienced (9.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman of the Board | 15.9yrs | NT$1.05m | no data | |
| Director | 5.9yrs | NT$138.00k | no data | |
| Deputy Chairman | 15.9yrs | NT$858.00k | no data | |
| Independent Director | 10.5yrs | NT$187.00k | no data | |
| Director | 10.5yrs | NT$138.00k | no data | |
| Director | 10.9yrs | NT$138.00k | no data | |
| Independent Director | 10.5yrs | NT$187.00k | no data | |
| Independent Director | 10.5yrs | NT$187.00k | no data | |
| Representative Director | 5.8yrs | NT$145.00k | no data |
10.5yrs
Average Tenure
Experienced Board: 4192's board of directors are seasoned and experienced ( 10.5 years average tenure).